Company Overview of Optherion, Inc.
Optherion, Inc., a biotechnology company, develops diagnostic and disease-modifying therapeutics for the management and treatment of early-stage age-related macular degeneration, dense deposit disease, atypical hemolytic uremic syndrome, and other chronic diseases involving the alternative complement cascade. The company was founded in 2005 and is based in New Haven, Connecticut.
555 Long Wharf Drive
The Maritime Center
New Haven, CT 06511
Founded in 2005
Key Executives for Optherion, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Optherion, Inc., please visit www.optherion.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.